Health AI Regulation: New Report & Key Insights
- A growing number of health artificial intelligence (AI) tools operate outside the U.S.Food and Drug Administration's (FDA) regulatory purview, according to a report.
- The report highlights that while the FDA regulates AI tools used for diagnosis, prevention, or treatment as medical devices, many others are governed by agencies such as the...
- Common categories of health AI not typically regulated as medical devices include administrative AI, clinical support tools, and consumer wellness apps.
Dive into the complex world of health AI regulation. A new report reveals that many artificial intelligence (AI) tools in healthcare operate outside the FDA’s direct oversight, leading to fragmented governance. This patchwork of federal and state regulations governs everything from administrative AI that streamlines prior authorizations to consumer wellness apps. The 21st Century Cures Act further complicates matters, defining the FDA’s authority. Explore how agencies like HHS and the FTC are shaping the landscape of healthcare with the primarykeyword being “health AI” which is influenced by a secondarykeyword “regulation.” For comprehensive insights, turn to News Directory 3. Discover what’s next in this evolving field.
Health AI Regulation: Patchwork Oversight Creates Uncertainty
A growing number of health artificial intelligence (AI) tools operate outside the U.S.Food and Drug Administration’s (FDA) regulatory purview, according to a report. These tools, which automate tasks, guide clinical decisions, and power wellness apps, are subject to a mix of federal rules, state laws, and industry standards.
The report highlights that while the FDA regulates AI tools used for diagnosis, prevention, or treatment as medical devices, many others are governed by agencies such as the Department of Health and human Services (HHS) and the Federal Trade Commission (FTC).
Common categories of health AI not typically regulated as medical devices include administrative AI, clinical support tools, and consumer wellness apps.
administrative AI automates prior authorization, detects billing fraud, forecasts staffing, and manages appointment scheduling. Clinical support tools integrated into electronic health records (EHRs) analyze patient data to suggest follow-up actions, informing but not replacing clinician judgment. Consumer wellness apps include fitness trackers and meditation apps.
The 21st Century Cures Act and AI Oversight
The 21st Century Cures act of 2016 defined the FDA’s authority over health software. It clarified that certain clinical decision support (CDS) tools are exempt from medical device classification if they meet specific criteria. These include not analyzing images or signals, using existing patient facts, supporting but not replacing clinical decisions, and having recommendations that providers can independently review.
Tools failing any criterion might potentially be considered Software as a Medical Device (SaMD) and fall under FDA oversight,creating a gray area for developers.
Oversight for non-medical device AI is distributed across federal and state agencies. The Office of the National Coordinator for Health IT (ONC) requires developers to disclose the intended use, logic, and data inputs of AI tools integrated into certified EHRs. However, this applies only to tools supplied by the EHR developer.
The Office for Civil Rights (OCR) enforces HIPAA for tools handling Protected Health Information (PHI) and prohibits algorithmic discrimination in federally funded health programs. the FTC can act against deceptive marketing claims and enforces the Health Breach Notification Rule for non-HIPAA-covered apps.
The Centers for Medicare & Medicaid Services (CMS) influences AI adoption through reimbursement policies. States are also increasingly active, with Colorado passing comprehensive AI risk laws and Illinois and Utah enacting targeted disclosure and consumer protection laws.
Jonathan Burks,Executive Vice President of Economic and Health Policy,said that as policymakers and agencies balance innovation with patient protection,a clear view of the regulatory landscape is essential.
What’s Next
policymakers and industry leaders must collaborate on clear frameworks and shared standards to support responsible innovation in health AI, ensure patient trust, and improve care quality.